Greener and expeditious one-pot synthesis of dihydropyrimidinone derivatives using non-commercial β-ketoesters via the Biginelli reaction

G. B. Dharma Rao*, B. Anjaneyulu and M. P. Kaushik*
Discovery Centre, Process Technology Development Division, Defence R&D Establishment, Jhansi Road, Gwalior – 474002, M.P., India. E-mail: gbdharmarao@gmail.com; mpkaushik@rediffmail.com; Fax: +91-751-2340042; Tel: +91-751-2343972

Received 3rd July 2014 , Accepted 26th August 2014

First published on 27th August 2014


Abstract

An expeditious synthesis of novel 3,4-dihydropyrimidin-2(1H)-one derivatives has been developed using a multi-component reaction involving the in situ generation of non-commercial β-ketoesters via transesterification of tert-butyl-β-ketoester with corresponding alcohol followed by the Biginelli reaction with arylaldehyde and urea in one-pot at 110 °C under green conditions.


Multi-component reactions1 (MCRs) emerged as a versatile synthetic tool for the construction of multi-functionalized and structurally diverse drug-like chemical entities as well as miscellaneous libraries of small molecules. In addition, they offer a substantial advantage over conventional linear-type synthesis in terms of speed, diversity and efficiency. The MCRs gained great importance, since these processes form a network of elementary reactions involving the different precursors towards one specific type of target product, thus making the process efficient and free of bi-products. One such outstanding MCR that produces a motivating class of nitrogen heterocycles is the venerable Biginelli reaction2 established by Italian chemist Pietro Biginelli (University of Florence) in 1893 for the synthesis of 3,4-dihydropyrimidinones (DHPMs) under strong acidic conditions. However, the yields of the products were modest.

3,4-Dihydropyrimidinones appear to be a class of honoured organic compounds and were extensively explored in bygone decades due to their different biological and therapeutic activities.3 Some of them have antitumor, antihypertensive, calcium channel blocker, α1a-antagonist, neuropeptide Y (NPY) antagonist, antibacterial, and anti-inflammatory activities. DHPM-derived scaffolds are also existing in the skeleton of several natural marine polycyclic guanidine alkaloids such as crambine, batzelladine B (potent HIV gp-120CD4 inhibitors), and ptilomycalin alkaloids.4

In over 120 years of study of the Biginelli reaction, only slight structural deviations in its three building blocks have been reported.5 However, to the best of our awareness, most of the literature precedents restricted only to β-ketoester which are commercially accessible as an active methylene building block in Biginelli reaction. Herein, we report the first example of the Biginelli reaction employing the in situ generation of non-commercial β-ketoester via transesterification of tert-butyl-β-ketoester with corresponding alcohol followed by Biginelli reaction with arylaldehyde and urea in one-pot at 110 °C under greener conditions.

Transesterification6 is a paramount organic transformation and provides an essential synthon for number of complex natural products, pheromones and additives for paints.7 In addition, transesterification alteration has also occupied a prominent position in industrial laboratories.8 The chemistry elaborated in transesterification is the interchange of alkoxy moiety in ester with alcohol to form a new ester.

Our own overview of the related literature has led to the conclusion that, in addition we found insignificant amount of reports for the construction of dihydropyrimidinone C5 ester derivatives. Desai et al. has reported9 that the synthesis of dihydropyrimidinones C5 ester derivatives is considerably long i.e. three step process and experienced from various downsides such as the prerequisite of drastic reaction conditions, prolonged reaction time, requirement of unusual experimental apparatus, use of toxic/expensive catalysts and tedious work-up procedure. Obviously, the stated protocol by Desai et al. not at all acceptable in the context of green synthesis. With an objective to develop a greener protocol recently we reported the dihydropyrimidinone C5 ester derivative synthesis using a two-step sequence.10

The current emphasis on improvement of sustainable chemical process has provided an emerging mission to those who applied chemistry in industry and academic research. The construction of chemical compounds or protocols by avoiding relatively volatile toxic solvents and perilous catalysts is essential in the present scenario of green synthesis.11,12 However, there is a growing awareness in finding processes that would provide well-organized alternatives to traditional Biginelli reaction and result in more economical and environmentally benign procedure.

tert-Butyl-β-ketoester readily underwent transesterification transformation with alcohol to form the corresponding new β-ketoester in presence of toluene/xylene as solvent under catalyst-free condition13 due to presence of better leaving group. By taking the benefit of bulkier group of tert-butyl-β-ketoester herein, we knock a viable protocol exceeds the boundaries associated with formerly occurred processes for the synthesis of dihydropyrimidin-2(1H)-one C5 ester derivatives (5) using in situ generation of non-commercial β-ketoester via transesterification of tert-butyl-β-ketoester (1) with corresponding alcohol (4) followed by Biginelli reaction with arylaldehyde (2) and urea (3) in one-pot at 110 °C under greener circumstances.

In continuation of our preceding work,14 there was a need to synthesize a large library of diversified dihydropyrimidinone derivatives with reducing time, excellent yields and outstanding biological activities. The finest conditions for the 3,4-dihydropyrimidin-2(1H)-one C5 ester derivatives were examined by making use of 4-methoxy benzaldehyde, tert-butyl-β-ketoester, urea and propargyl alcohol were taken as model substrates under greener conditions. It was found that when tert-butyl-β-ketoester, arylaldehyde, urea and propargyl alcohol were used in the ratio of 1[thin space (1/6-em)]:[thin space (1/6-em)]1[thin space (1/6-em)]:[thin space (1/6-em)]1.2[thin space (1/6-em)]:[thin space (1/6-em)]1.5 under solvent and catalyst free conditions at 110 °C gave best result towards the formation of title product (Table 1, entry 7). The use of increased quantity of propargyl alcohol did not enhance the desired product yield, whereas lower amount of propargyl alcohol gave the modest yield due to the equilibrium of transesterification. With the curiosity in finding the reaction pathway, we analyzed the reaction mixture of model reactants with time intervals of 10 min, 30 min, 1 h, 2 h and 3 h using ESI-MS technique. From the above experiments we observed propargyl β-ketoester (Scheme 1, 6, ESI-MS = 141.32, M + 1) after 10 min, the products i.e. dihydropyrimidinones with both propargyl β-ketoester and tert-butyl β-ketoester (Scheme 1, 5 and 7, ESI-MS = 301.58 & 319.16, M + 1) after 1 h and finally obtained the desired dihydropyrimidinones with propargyl β-ketoester (Scheme 1, 5, ESI-MS = 301.58, M + 1) after 3 h of reaction. On the basis of above observations, it can be concluded that the reaction of four components in one-pot follows two reaction pathways (transesterification followed by Biginelli reaction or Biginelli reaction followed by transesterification) simultaneously towards the construction of desired title product. This is essentially because both the synthon species (propargyl β-ketoester and tert-butyl-β-ketoester) were willingly participated in Biginelli reaction with arylaldehyde (2) and urea (3).

Table 1 Synthesis of dihydropyrimidin-2(1H)-one derivatives using non-commercial β-ketoesters under greener conditionsa

image file: c4ra06587e-u1.tif

Entry Aldehyde (2) Alcohol (4) Product (5) M.P (°C) (%)Yieldb, (ref.)
Method-A (1 step per 3 h) Method-B (2 steps per 6 h)
a Reaction conditions: tert-butyl-β-ketoester (1.0 mmol), arylaldehyde (1.0 mmol), urea (1.2 mmol) and alcohol (1.5 mmol) under solvent and catalyst free conditions at 110 °C.b Isolated yields.
1 image file: c4ra06587e-u2.tif image file: c4ra06587e-u3.tif image file: c4ra06587e-u4.tif 148–150 92 86
2 image file: c4ra06587e-u5.tif image file: c4ra06587e-u6.tif image file: c4ra06587e-u7.tif 152–154 92 90 (ref. 10)
3 image file: c4ra06587e-u8.tif image file: c4ra06587e-u9.tif image file: c4ra06587e-u10.tif 128–130 90 87 (ref. 10)
4 image file: c4ra06587e-u11.tif image file: c4ra06587e-u12.tif image file: c4ra06587e-u13.tif 200–202 92 90 (ref. 10)
5 image file: c4ra06587e-u14.tif image file: c4ra06587e-u15.tif image file: c4ra06587e-u16.tif 178–180 90 92 (ref. 10)
6 image file: c4ra06587e-u17.tif image file: c4ra06587e-u18.tif image file: c4ra06587e-u19.tif 194–196 90 85 (ref. 10)
7 image file: c4ra06587e-u20.tif image file: c4ra06587e-u21.tif image file: c4ra06587e-u22.tif 150–152 92 89
8 image file: c4ra06587e-u23.tif image file: c4ra06587e-u24.tif image file: c4ra06587e-u25.tif 174–176 90 83
9 image file: c4ra06587e-u26.tif image file: c4ra06587e-u27.tif image file: c4ra06587e-u28.tif 156–158 87 78
10 image file: c4ra06587e-u29.tif image file: c4ra06587e-u30.tif image file: c4ra06587e-u31.tif 172–174 91 85
11 image file: c4ra06587e-u32.tif image file: c4ra06587e-u33.tif image file: c4ra06587e-u34.tif 166–168 94 89
12 image file: c4ra06587e-u35.tif image file: c4ra06587e-u36.tif image file: c4ra06587e-u37.tif 182–184 92 86
13 image file: c4ra06587e-u38.tif image file: c4ra06587e-u39.tif image file: c4ra06587e-u40.tif 180–182 87 78
14 image file: c4ra06587e-u41.tif image file: c4ra06587e-u42.tif image file: c4ra06587e-u43.tif 196–198 91 83
15 image file: c4ra06587e-u44.tif image file: c4ra06587e-u45.tif image file: c4ra06587e-u46.tif 184–186 89 83
16 image file: c4ra06587e-u47.tif image file: c4ra06587e-u48.tif image file: c4ra06587e-u49.tif 158–160 90 82 (ref. 10)
17 image file: c4ra06587e-u50.tif image file: c4ra06587e-u51.tif image file: c4ra06587e-u52.tif 178–180 72 58
18 image file: c4ra06587e-u53.tif image file: c4ra06587e-u54.tif image file: c4ra06587e-u55.tif 168–170 81 62



image file: c4ra06587e-s1.tif
Scheme 1 Reaction mixture is analyzed at different time intervals using ESI-MS technique.

When the above mentioned reaction conditions were applied to the methyl β-ketoester, ethyl β-ketoester, isobutyl β-ketoester instead of tert-butyl-β-ketoester with propargyl alcohol for Biginelli four component reaction and we observed that the dihydropyrimidinones with methyl, ethyl, isobutyl β-ketoesters (Fig. 1, 8, 9, 10). At this point propargyl alcohol behaved as a solvent but not as a precursor in novel four component cascade reaction owing to the existence of equilibrium.


image file: c4ra06587e-f1.tif
Fig. 1 Dihydropyrimidinones of methyl/ethyl/isobutyl β-ketoesters (ESI-MS = 277.18, 291.62, 319.38, M + 1).

The applicability of these optimized reaction conditions and usefulness of this protocol has also been extended to diversified arylaldehydes with various functional substitutions and variety of alcohols. The protocol seems to be tolerant with both electron donating and electron withdrawing substituents on arylaldehyde and accessible with different alcohol provide the corresponding anticipated dihydropyrimidin-2(1H)-one C5 ester in high yield and all the results were appended in Table 1.

The newly advanced protocol (method-A) is also compared with earlier adjusted bang10 (method-B) and we found that relatively comparable yields in both protocols. The novel four component one-pot Biginelli reaction towards the construction of dihydropyrimidin-2(1H)-one C5 ester is offers more advantages than compare with previously reported two step reaction in terms of shorter reaction time, mild reaction conditions, cost-effectiveness, atom economy and diminish the synthetic reaction steps from two to one.

Based on literature precedents, a plausible reaction mechanism for the observed dihydropyrimidin-2(1H)-one C5 ester derivatives is depicted in Scheme 2. In trans-acetoacetylation (transesterification) transformation, tert-butyl-β-ketoester (1) underwent trans-acetoacetylation through acetylketene intermediate13 to form new β-ketoester (6) with alcohol (4). In the Biginelli reaction, the imine intermediate (11) was formed by the combination of arylaldehyde (2) and urea (3) which is interacted with keto–enol form of new β-ketoester (6) to form the adduct product (12). The cyclisation followed by dehydration occurred during the course of final desired dihydropyrimidin-2(1H)-one C5 ester derivative (5) with corresponding aldehyde and alcohol.


image file: c4ra06587e-s2.tif
Scheme 2 Proposed reaction pathway for dihydropyrimidin-2(1H)-one C5 ester derivatives.

In conclusion, we have established a simple, environmentally benign and straight forward one-pot protocol for the efficient synthesis of dihydropyrimidin-2(1H)-ones C5 ester derivatives through in situ generation of new β-ketoester (transesterification) followed by Biginelli reaction using available laboratory reagents under solvent and catalyst free conditions at 110 °C. This method is endowed with outstanding features such as, simple operation, mild reaction conditions, easy work-up procedure, short reaction time, no hazardous catalysts and solvents. This protocol is also environmentally benign and commercially viable.

Experimental section

An oven-dried 25 ml round bottomed flask equipped with a refluxed condenser was charged with arylaldehyde (1.0 mmol) and urea (1.2 mmol). The precursors were finely powdered and mixed together and allowed to mechanical stirring for 30 min at room temperature. The tert-butyl-β-ketoester (1.0 mmol) and an alcohol (1.5 mmol) were added to above mixture subsequently. The resulting reaction mixture was heated for 3 h at 110 °C (oil bath) with constant stirring till the reaction was completed. The progress of reaction was monitored by TLC. After completion of reaction as indicated on TLC, the contents of reaction mixture was cooled to room temperature and the crude reaction mixture was crushed and washed with chilled water (15 ml × 3), filtered and dried under vacuum. For analytically pure products, the final solid mass was washed with diethyl ether (10 ml × 3) to remove the un-reacted reactants to afford the pure product in 85–94% yield.

Acknowledgements

The authors are gratified to Director, DRDE, Gwalior for his enthusiastic interest and invariable encouragement.

Notes and references

  1. (a) H. Bienayme, C. Hulme, G. Oddon and P. Schmitt, Chem.–Eur. J., 2000, 6, 3321–3329 CrossRef CAS; (b) A. Domling and I. Ugi, Angew. Chem., Int. Ed., 2000, 39, 3168–3210 CrossRef CAS.
  2. P. Biginelli, Gazz. Chim. Ital., 1893, 23, 360 Search PubMed.
  3. (a) K. S. Atwal, B. N. Swanson, S. E. Unger, D. M. Floyd, S. Moreland, A. Hedberg and B. C. O'Reilly, J. Med. Chem., 1991, 34, 806 CrossRef CAS; (b) G. J. Grover, S. Dzwonczyk, D. M. McMullen, D. E. Normandin, C. S. Parham, P. G. Sleph and S. Moreland, J. Cardiovasc. Pharmacol., 1995, 26, 289 CrossRef CAS PubMed; (c) G. C. Rovnyak, S. D. Kimball, B. Beyer, G. Cucinotta, J. D. Dimarco, J. Gougoutas, A. Hedberg, M. Malley, J. P. McCarthy, R. Zhang and S. Moreland, J. Med. Chem., 1995, 38, 119 CrossRef CAS; (d) K. S. Atwal, G. C. Rovnyak, B. C. O'Reilly and J. Schwartz, J. Org. Chem., 1989, 54, 5898 CrossRef CAS; (e) E. H. Hu, D. R. Sidler and U. H. Dolling, J. Org. Chem., 1998, 63, 3454 CrossRef CAS; (f) C. O. Kappe, W. M. F. Fabian and M. A. Semones, Tetrahedron, 1997, 53, 2803 CrossRef CAS.
  4. (a) A. S. Franklin, S. K. Ly, G. H. Mackin, L. E. Overman and A. J. Shaka, J. Org. Chem., 1999, 64, 1512 CrossRef CAS PubMed; (b) C. O. Kappe, Eur. J. Med. Chem., 2000, 1043, 35 Search PubMed.
  5. (a) A. J. Builla, R. Alajarin, P. Jordon and J. J. Vaquero, Synthesis, 1995, 389 Search PubMed; (b) A. Shaabani, A. Rahmati and S. Naderi, Bioorg. Med. Chem. Lett., 2005, 15, 5553 CrossRef CAS PubMed; (c) S. Tu, Q. Shao, D. Zhou, L. Cao, F. Shi and C. Li, J. Heterocycl. Chem., 2007, 44, 1401 CrossRef CAS PubMed; (d) S. V. Ryabukhin, A. S. Plaskon, S. S. Bondarenko, E. N. Ostapchuk, O. O. Grygorenko, O. V. Shishkin and A. A. Tolmachev, Tetrahedron Lett., 2010, 51, 4229–4232 CrossRef CAS PubMed; (e) W. Jie-Ping and P. Yuan-Jiang, Chem. Commun., 2009, 2768–2770 Search PubMed; (f) B. L. Nilsson and L. E. Overman, J. Org. Chem., 2006, 71, 7706–7714 CrossRef CAS PubMed; (g) A. Csampai, A. Z. Gyorfi, Gy. I. Turos and P. Sohar, J. Organomet. Chem., 2009, 694, 3667 CrossRef CAS PubMed; (h) M. B. Deshmukh, S. M. Salunkhe, D. R. Patil and P. V. Anbhule, Eur. J. Med. Chem., 2009, 44, 2651 CrossRef CAS PubMed.
  6. (a) T. Fujita, M. Tanaka, Y. Norimine and H. Suemune, J. Org. Chem., 1997, 62, 3824 CrossRef CAS; (b) G. Shapiro and M. Marli, J. Org. Chem., 1997, 62, 7096 CrossRef CAS; (c) G. B. Dharma Rao and M. P. Kaushik, Tetrahedron Lett., 2011, 52, 5104 CrossRef CAS PubMed; (d) G. B. Dharma Rao and M. P. Kaushik, Int. Arch. Appl. Sci. Technol., 2013, 13, 25–29 Search PubMed.
  7. (a) V. S. Parmar, A. K. Prasad, N. K. Sharma, K. S. Bisht, R. Sinha and P. Taneja, Pure Appl. Chem., 1992, 64, 1135–1139 CrossRef CAS; (b) J. Otera, Chem. Rev., 1993, 93, 1449 CrossRef CAS.
  8. U. Schuchardt, R. M. Vargas and G. Gelbard, J. Mol. Catal. A: Chem., 1996, 109, 37 CrossRef CAS , and references therein.
  9. B. Desai, D. Dallinger and C. O. Kappe, Tetrahedron, 2006, 62, 4651–4664 CrossRef CAS PubMed.
  10. G. B. Dharma Rao, B. N. Acharya and M. P. Kaushik, Tetrahedron Lett., 2013, 54, 6644–6647 CrossRef CAS PubMed.
  11. (a) P. T. Anastas and E. S. Beach, Green Chem. Lett. Rev., 2008, 1, 9–24 CrossRef; (b) S. Tang, R. Bourne, R. Smith and M. Polyakoff, Green Chem., 2008, 10, 268–269 RSC.
  12. (a) W. Du, Q. Trouong, H. Qi, Y. Guo, H. R. Chobanian, W. K. Hagmann and J. J. Hale, Tetrahedron Lett., 2007, 48, 2231–2235 CrossRef CAS PubMed; (b) A. Albini and M. Fagnoni, ChemSusChem, 2008, 1, 63–66 CrossRef CAS PubMed; (c) P. Vivek and R. S. Verma, Tetrahedron Lett., 2007, 48, 7343–7346 CrossRef PubMed.
  13. W. D. Nottingham and J. S. Witzeman, J. Org. Chem., 1991, 56, 1713–1718 CrossRef.
  14. (a) G. B. Dharma Rao, B. N. Acharya, S. K. Verma and M. P. Kaushik, Tetrahedron Lett., 2011, 52, 809 CrossRef PubMed; (b) G. B. Dharma Rao, M. P. Kaushik and A. K. Halve, Tetrahedron Lett., 2012, 53, 2741–2744 CrossRef CAS PubMed; (c) G. B. Dharma Rao, M. P. Kaushik and A. K. Halve, Heterocycl. Lett., 2012, 2, 411–418 CAS; (d) G. B. Dharma Rao, B. Anjaneyulu and M. P. Kaushik, Tetrahedron Lett., 2014, 55, 19–22 CrossRef CAS PubMed.

Footnote

Electronic supplementary information (ESI) available: General details, experimental procedures, characterisation data, and copies of 1H and 13C NMR for selected compounds. See DOI: 10.1039/c4ra06587e

This journal is © The Royal Society of Chemistry 2014